A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer (Q33383818)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer |
scientific article |
Statements
1 reference
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer (English)
1 reference
Robert J Amato
1 reference
Jaroslaw Jac
1 reference
Sarah Giessinger
1 reference
Somyata Saxena
1 reference
James P Willis
1 reference
1 reference
Identifiers
1 reference